Global Recombinant Human EGF Market to Record Protruding Growth With US$ 18,800.7 Million By 2027

April 2021 | Report Format: Electronic (PDF)

The increased diabetes incidence is likely to fuel growth in the market growth, as recombinant human EGF is used to treat the diabetic ulcer. For example, as per research issued in September 2019 by the International Diabetes Federation, the worldwide incidence of diabetes is anticipated to be 9.3 percent; however, this figure is expected to rise to 10.2 percent by 2030. According to the same source, the number of individuals suffering from diabetes worldwide is anticipated to rise by 51% by 2045.

Growing R&D initiatives by governmental and private organizations are likely to propel the worldwide recombinant human EGF market forward. For example, a report conducted in the Medical Military Journal in March 2021 looked into the possible efficacy of recombinant human EGF in the healing process when combined with vacuum sealing drainage (VSD). Both VSD and EGF are essential in wound healing and have been shown to improve healing when taken together. This is believed to assist reduce treatment duration by shortening wound healing time. Such improvements are likely to open up new avenues for the recombinant human EGF market.

North America is predicted to account for a large market size during the forecast period, whilst the Asia-Pacific region is anticipated to exhibit significant development in the recombinant human EGF industry due to emerging market tactics such as partnerships and collaborations. For example, in 2019, Uni-Bio Science Group Limited, a China-based biopharmaceutical business, announced a joint venture with Medlink, a U.K.-based software solutions company, to boost the commercialization of GeneTime, a recombinant EGF-based medication for ulcers therapy.

Request a Free Sample Copy: Recombinant Human EGF Market Report

Recombinant Human EGF Market Report Highlights

• The worldwide recombinant human EGF industry is forecasted to develop at a CAGR of 9.3 percent between 2021 and 2028, owing to increased research in the area of recombinant human EGF.
• FUJIFILM, a Japanese global corporation, has purchased Irvine Scientific Sales Company, Inc., a cellular media expert, in order to broaden its portfolio of cell culture media products, which includes recombinant human EGF. This is predicted to propel the recombinant human EGF industry forward.
• The establishment of reimbursement regulations for recombinant human EGF is projected to promote the growth of the recombinant human EGF market. For example, the national reimbursement medicine listing was updated to impose limits on Healin, a recombinant human EGF protein used to treat wounds. Shanghai Haohai Biological Technology Co., Ltd. manufactures the product, which is classified as a class B medical insurance product.

RECOMBINANT HUMAN EGF MARKET SEGMENTATION

The research report published by Market Research Strategy contains industry segments, as below-

Recombinant Human EGF Market Product Type Outlook (Revenue, USD Million, 2016 - 2027)

• Amphiregulin
• Betacellulin
• Epigen
• Heparin Binding-EGF
• Neuregulins
• Transforming Growth Factor-α
• Others

Recombinant Human EGF Market Purity Outlook (Revenue, USD Million, 2016 - 2027)

• 98% SDS-PAGE
• 95%-98% SDS-PAGE
• <95% SDS-PAGE

Recombinant Human EGF Market Carrier Type Outlook (Revenue, USD Million, 2016 - 2027)

• Carrier Protein
• Carrier Free

Recombinant Human EGF Market Formulation Outlook (Revenue, USD Million, 2016 - 2027)

• Liquid
• Lyophilized Powder
• Others

Recombinant Human EGF Market Application Outlook (Revenue, USD Million, 2016 - 2027)

• Brain Tumor Therapy
• Gastrointestinal Ulceration
• Wound Healing
• Others

Recombinant Human EGF Market Regional Outlook (Revenue, USD Million, 2016 - 2027)

• North America (U.S., and Canada)
• Europe (Germany, U.K., France, Italy, Spain etc.)
• Asia-Pacific (China, India, Japan, Indonesia, Malaysia, Australia, South Korea, etc.)
• South America (Brazil, Mexico, Argentina etc.)
• Middle East & Africa (Saudi Arabia, Kuwait, UAE, South Africa etc.)

List of Key Players- Recombinant Human EGF Market

• Abcam PLC
• BioLegend, Inc.
• BioVision, Inc.
• Cell Guidance Systems Ltd.
• Cell Sciences, Inc.
• Creative BioMart
• EnQuire BioReagents
• Eurofins DiscoverX
• FUJIFILM Irvine Scientific, Inc.
• Miltenyi Biotec
• PeproTech, Inc.
• Prospec-Tany TechnoGene Ltd
• R&D Systems
• RayBiotech, Inc.
• ScienCell Research Laboratories
• Sino Biological Inc.
• STEMCELL Technologies Inc.
• Thermo Fisher Scientific
• Tonbo Biosciences

About Market Research Strategy:

Market Research Strategy (MRS) is a dedicated and disciplined market research firm that delivers authentic consulting services with accurate data forecasting for research-related services. The positive and result-oriented approaches implemented by us are beneficial in identifying the market challenges of any brand or start-up company to penetrate the competitive business space.

MRS also supports numerous organizations with its syndicate data and research reports to establish and survive in the market by grabbing the available market opportunities. Our vast experience and huge client database turn out to be our wealth and also secures our market position at the top of the list. Besides, we make use of every single piece of information, mined from authentic sources, into a valuable asset of the report; aiding our clients with informed business decisions.

Contact Us:

Market Research Strategy

USA Phone: +1 9176726599

Business Email: sales@marketresearchstrategy.com

Website: https://marketresearchstrategy.com/